Test Price
2,800 AED✅ Home Collection Available
MRPS22 Gene Combined Oxidative Phosphorylation Deficiency Type 5 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MRPS22 لمرض نقص الفسفرة التأكسدية المركب من النوع الخامس في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Clinical Excellence & Patient-Centric Assurance
- ✓ 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified Genomic Sequencing with dual platform verification.
- ✓ Hospital-Grade Cold-Chain Home Collection – Complimentary VIP phlebotomy service (8 AM–11 PM) across UAE, including Dubai, Abu Dhabi, Sharjah & Northern Emirates.
- ✓ Post-Test Telephonic Clinical Guidance – Dedicated molecular geneticist counsels on results interpretation and next steps.
- ✓ Instant Insurance Verification – WhatsApp +971 54 548 8731 for direct billing pre‑approval.
يوفر هذا الاختبار الجيني الدقيق تشخيصًا موثوقًا لنقص الفسفرة التأكسدية المركب من النوع الخامس، مع استشارة وراثية شاملة وخدمة سحب منزلي فاخرة بمعايير دولية.
Clinical Overview
This next‑generation sequencing test analyzes the entire coding region of the MRPS22 gene to detect pathogenic variants causing Combined Oxidative Phosphorylation Deficiency Type 5 (COXPD5).
يُعد تحليل جين MRPS22 ضرورياً لتأكيد التشخيص في حالات اعتلال الميتوكوندريا الوراثي النادر.
| Feature | Our Test (MRPS22‑NGS) | Closest Alternative (Broad Metabolic Panel) |
|---|---|---|
| Precision | Single‑gene resolution; 99.9% base‑calling accuracy | Multi‑analyte, non‑specific; may miss point mutations |
| Methodology | NGS (Illumina® platform, 150x mean depth) | Biochemical assays / multiplex PCR |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks (non‑genetic) |
| Interpretative Report | ACMG‑based, with carrier status & familial risk | Quantitative metabolites only |
Physician Insight & Safety Protocol
“This test is a critical piece of the diagnostic puzzle—it must always be correlated with clinical phenotype, family history, and functional studies. A negative result does not exclude mitochondrial disease; a positive result empowers early intervention and reproductive planning. Your care journey deserves the utmost empathy and precision.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
⚠ Medication Alert: Do not discontinue or adjust any prescribed medication prior to or during testing without explicit guidance from your treating physician.
Exclusion Criteria & Emergency Red Flags
- Unwillingness to provide informed genetic consent (mandatory under UAE CDS Law 2026 for minors).
- Acute metabolic decompensation (severe lethargy, intractable vomiting, hypoglycaemia).
- Neurological deterioration: sudden loss of milestones, seizures, or altered consciousness.
- Haemodynamic instability requiring immediate emergency care.
If any red flag appears, seek emergency medical attention before proceeding with elective genetic testing.
Frequently Asked Questions
What is the MRPS22 gene test used for?
It identifies DNA variants in the MRPS22 gene to confirm a diagnosis of Combined Oxidative Phosphorylation Deficiency Type 5, a rare mitochondrial disorder. يُستخدم لتأكيد تشخيص مرض نقص الفسفرة التأكسدية المركب من النوع الخامس عبر الكشف عن الطفرات الجينية.
How is the sample collected, and does it require fasting?
We collect a small whole blood sample (2–5 mL in EDTA tube) or DNA via FTA card; no fasting is necessary for this genetic. يتم سحب عينة دم صغيرة أو استخدام بطاقة FTA، ولا يتطلب الاختبار أي صيام.
When will I receive my results and what support is available?
Results are available in 3–4 weeks, and you will receive a telephonic genetic counselling session to explain the findings. تصدر النتائج خلال 3–4 أسابيع، مع جلسة استشارة وراثية هاتفية لشرح التفاصيل.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians